We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Mindray to Acquire 75% Stake in DiaSys

By LabMedica International staff writers
Posted on 04 Aug 2023
Print article
Image: Mindray has agreed to acquire 75% equity interest in DiaSys (Photo courtesy of Mindray)
Image: Mindray has agreed to acquire 75% equity interest in DiaSys (Photo courtesy of Mindray)

Mindray (Shenzhen, China) has agreed to acquire a 75% equity interest in DiaSys Diagnostic Systems GmbH (Holzheim, Germany) through its Dutch subsidiary for an all-cash preliminary purchase price of approximately EUR 115 million with the final amount to be determined as of closing. The agreement is slated to be finalized later this year, pending regulatory approvals and the granting of regulatory approvals. Upon finalizing the transaction, Mindray will hold a 75% stake in DiaSys and consolidate DiaSys and its subsidiaries. DiaSys's wide range of clinical chemistry systems, manufacturing capabilities for controls and calibrators, and a global network of manufacturing and distribution sites synergize fully complement Mindray's extensive hematology and immunoassays product range, creating a plethora of market opportunities.

Recognized globally, DiaSys has over 30 years of experience in the in-vitro diagnostics (IVD) field with production facilities spread across Europe, APAC, and Latin America. Mindray intends to utilize DiaSys's international team of professionals and global supply platforms to expedite the construction of overseas supply chains, aiming for further expansion into global medium to large volume customer segments and delivering more timely and comprehensive professional services to clients. Moreover, DiaSys's vast experience in clinical chemistry is anticipated to bring synergistic value to Mindray's IVD business. DiaSys’s expertise in developing and producing IVD controls and calibrators will complement Mindray’s IVD product line and enhance its system performance.

“We are very pleased to see this collaboration come to fruition, as Mindray’s and DiaSys’ businesses strongly complement each other,” said Wu Hao, President of Mindray. “Through this acquisition, Mindray will effectively improve its overseas supply chain platform and support the penetration of our IVD business in the medium to large customer segments. We look forward to both parties jointly realizing synergies and creating greater value for our customers.”

“DiaSys with its comprehensive range of products and global manufacturing footprints, and Mindray with its total IVD solutions and worldwide network, are ideal partners for lifting synergies in the IVD field,” added Dr. Günther Gorka, DiaSys’s Founder. “The individual strengths of both partners will support each other and help for a common and sustainable success in all regions of the world.”

Related Links:
Mindray
DiaSys Diagnostic Systems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.